39 results
DEFA14A
ELYM
Eliem Therapeutics Inc
11 Apr 24
Additional proxy soliciting materials
8:10am
for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous … ) Dose 200 mg, IV (SC†) 300 mg, IV 600+ mg, IV Frequency Q3M/Q6M (induction + maintenance) Q6M (induction + maintenance) Q1W/Q2W (chronic)
TNT119 Early
8-K
EX-99.2
ELYM
Eliem Therapeutics Inc
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
(Approved) Dose 200 mg, IV (SC†) 300 mg, IV 600+ mg, IV Frequency Q3M/Q6M (induction + maintenance) Q6M (induction + maintenance) Q1W/Q2W (chronic … -associated vasculitides, SSc = Systemic sclerosis; CIDP = Chronic inflammatory demyelinating polyradiculoneuropathy, IgG4-RD = IgG4 related disease, RA
8-K
EX-99.1
ELYM
Eliem Therapeutics Inc
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders
8-K
EX-99.1
nf8pzmjaf8ds
20 Jul 23
Eliem Therapeutics Announces Plans to Explore Strategic Alternatives
6:55am
8-K
EX-99.1
j6e 0tixouyide89rm
11 May 23
Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights
4:12pm
8-K
EX-99.2
0p37te5a
11 May 23
Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights
4:12pm
8-K
EX-99.2
0uyrtxf xzt4
14 Nov 22
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
6:10am
8-K
EX-99.1
xgagf5 2lhueaq3
14 Nov 22
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
6:10am
8-K
EX-99.2
u53z nkpvlgz
5 Oct 22
Eliem Therapeutics Provides Update on Pipeline Progress
7:47am
8-K
EX-99.1
342z h2zew8j78
5 Oct 22
Eliem Therapeutics Provides Update on Pipeline Progress
7:47am
8-K
EX-99.1
6gzfdz hh
15 Aug 22
Eliem Therapeutics Reports Second Quarter Financial and Business Highlights
6:15am
8-K
EX-99.1
5bpte56c63 ihetqf7i
16 May 22
Eliem Therapeutics Reports First Quarter Financial and Business Highlights
6:24am